Engineering ex vivo T-cell expansion for CAR-T therapy: bridging biological fidelity and bioprocess scalability through platforms, functional consumables, and integrated closed manufacturing.
Journal: Frontiers in immunology
•
Abstract
Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.
Subjects & Keywords
How to Cite this Article
Wu Q, Jiang M, Li Y, et al. (2026). "Engineering ex vivo T-cell expansion for CAR-T therapy: bridging biological fidelity and bioprocess scalability through platforms, functional consumables, and integrated closed manufacturing.". Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1981337